コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 euroinflammation (e.g. neurodegenerative and neuropsychiatric diseases).
2 phenotypes associated with genetic forms of neuropsychiatric disease.
3 nd subcortical regions associated with human neuropsychiatric disease.
4 ess that can become compromised in aging and neuropsychiatric disease.
5 subtle molecular changes that contribute to neuropsychiatric disease.
6 ibutions to fear and anxiety and its role in neuropsychiatric disease.
7 s could lead to cognitive control failure in neuropsychiatric disease.
8 human brain organoids as in vitro models of neuropsychiatric disease.
9 all fluctuations in protein quantity lead to neuropsychiatric disease.
10 lar events that, when disrupted, can lead to neuropsychiatric disease.
11 al care, such as evaluation for metabolic or neuropsychiatric disease.
12 nosology of biomarkers used in the study of neuropsychiatric disease.
13 processes disrupted in neurodegenerative and neuropsychiatric disease.
14 upporting the utility of phNPCs for studying neuropsychiatric disease.
15 ng how researchers conceptualize and explore neuropsychiatric disease.
16 utilization, highlighting their relevance to neuropsychiatric disease.
17 isk and (potentially) protective factors for neuropsychiatric disease.
18 ng in the evaluation of somatic mutations in neuropsychiatric disease.
19 could have applicability to other studies in neuropsychiatric disease.
20 ements established gene-mapping paradigms in neuropsychiatric disease.
21 vitro studies informing novel therapies in a neuropsychiatric disease.
22 herapeutic interest in neurodegeneration and neuropsychiatric disease.
23 at the core of disturbed social behavior in neuropsychiatric disease.
24 and susceptibility to neurodegenerative and neuropsychiatric disease.
25 ay a role in synaptic dysfunction underlying neuropsychiatric disease.
26 ycles and synaptic dysfunction in a model of neuropsychiatric disease.
27 ry synaptic plasticity and its relevance for neuropsychiatric disease.
28 emerged as a potential therapeutic target in neuropsychiatric disease.
29 tion may contribute to behaviors observed in neuropsychiatric disease.
30 ptome limits interpretation of risk loci for neuropsychiatric disease.
31 in the study of circuit function relevant to neuropsychiatric disease.
32 f the loop has been implicated previously in neuropsychiatric disease.
33 in both normal animals and animal models of neuropsychiatric disease.
34 nderstanding human physiology, behavior, and neuropsychiatric disease.
35 model might be more generally applicable to neuropsychiatric disease.
36 ensive care unit (ICU)-acquired weakness and neuropsychiatric disease.
37 highly penetrant and common genetic cause of neuropsychiatric disease.
38 rve as a useful biomarker in mouse models of neuropsychiatric disease.
39 obiologic systems that are often abnormal in neuropsychiatric disease.
40 sive topic of study despite its relevance to neuropsychiatric disease.
41 discussed with regard to a monkey model for neuropsychiatric disease.
42 egies of study and therapeutics in childhood neuropsychiatric disease.
43 [123I]beta-CIT in serial evaluation of human neuropsychiatric disease.
44 human neural development and dysfunction in neuropsychiatric disease.
45 arly neurodevelopment, a critical period for neuropsychiatric disease.
46 r spiritual context to avoid misdiagnosis of neuropsychiatric disease.
47 he assembly of cortical circuits and lead to neuropsychiatric disease.
48 irculation increase the offspring's risk for neuropsychiatric disease.
49 ssion tomography, mainly reflects gliosis in neuropsychiatric disease.
50 is critical for modeling, and understanding neuropsychiatric disease.
51 s and informing new treatment strategies for neuropsychiatric disease.
52 e, providing a powerful tool in the study of neuropsychiatric disease.
53 ortical evolution, and the cellular basis of neuropsychiatric disease.
54 nvestigations of it's role in the genesis of neuropsychiatric disease.
55 r loss or dysfunction is implicated in human neuropsychiatric disease.
56 lt offspring brain, mimicking those in human neuropsychiatric disease.
57 s associated with neurological disorders and neuropsychiatric disease.
58 n for aggression arising in certain forms of neuropsychiatric disease.
59 transcriptional mechanisms that may underlie neuropsychiatric disease.
60 indles may represent heritable biomarkers of neuropsychiatric disease.
61 olding protein that has been associated with neuropsychiatric disease.
62 ge at the level of the glia to contribute to neuropsychiatric disease.
63 al quantitative variation and in relation to neuropsychiatric disease.
64 anifestation of a broader pattern of chronic neuropsychiatric disease.
65 e functional relevance of such regulation to neuropsychiatric disease.
66 tation-transcription coupling both relate to neuropsychiatric disease.
67 ological basis of reward- and stress-related neuropsychiatric disease.
68 for future translational relevance to human neuropsychiatric disease.
69 aviors could become targets for treatment of neuropsychiatric diseases.
70 raits (pleiotropy), including autoimmune and neuropsychiatric diseases.
71 related phenotypes, including cognition and neuropsychiatric diseases.
72 we demonstrate clinical use of the model in neuropsychiatric diseases.
73 rol of chronic infectious, inflammatory, and neuropsychiatric diseases.
74 known to cognitive neuroscience and in most neuropsychiatric diseases.
75 ting abilities, are core features of several neuropsychiatric diseases.
76 rged as a promising therapeutic strategy for neuropsychiatric diseases.
77 ls provide a powerful opportunity to examine neuropsychiatric diseases.
78 d patients with specific treatment-resistant neuropsychiatric diseases.
79 s in understanding and treating a variety of neuropsychiatric diseases.
80 ognitive processing and disrupted in diverse neuropsychiatric diseases.
81 h is critical for studying disorders such as neuropsychiatric diseases.
82 etween ASDs and other neurodevelopmental and neuropsychiatric diseases.
83 in these processes that are observed in many neuropsychiatric diseases.
84 ous associations with developmental delay or neuropsychiatric diseases.
85 to be upregulated in patients suffering from neuropsychiatric diseases.
86 lligence measures and capacity is reduced in neuropsychiatric diseases.
87 l thickness as an intermediate phenotype for neuropsychiatric diseases.
88 to risk for bipolar disorder and other major neuropsychiatric diseases.
89 Stress is a major risk factor for numerous neuropsychiatric diseases.
90 also credited as a major player in a host of neuropsychiatric diseases.
91 omplex brain related traits, including human neuropsychiatric diseases.
92 ciated with a wide range of neurological and neuropsychiatric diseases.
93 ion-deficit hyperactivity disorder and other neuropsychiatric diseases.
94 ique for a variety of movement disorders and neuropsychiatric diseases.
95 lex behaviors and might be perturbed in some neuropsychiatric diseases.
96 served associations between DAT genotype and neuropsychiatric diseases.
97 ws into the pathophysiology and treatment of neuropsychiatric diseases.
98 an important concept in the study of complex neuropsychiatric diseases.
99 r, neuronal development, and the sequella of neuropsychiatric diseases.
100 ruption of this function may underlie severe neuropsychiatric diseases.
101 matic and neuroprotective therapy of various neuropsychiatric diseases.
102 considered as candidates for diabetes and/or neuropsychiatric diseases.
103 mimetics for the potential treatment of the neuropsychiatric diseases.
104 thies contribute to cognitive dysfunction in neuropsychiatric diseases.
105 dverse effects of deep brain stimulation for neuropsychiatric diseases.
106 function has been implicated in epilepsy and neuropsychiatric diseases.
107 children are at increased risk of developing neuropsychiatric diseases.
108 and treatment, especially in neurologic and neuropsychiatric diseases.
109 increase the prevalence of anxiety and other neuropsychiatric diseases.
110 neages, conceivably explaining mitigation of neuropsychiatric diseases.
111 strategies to address neurodegenerative and neuropsychiatric diseases.
112 fic symptoms that are shared across multiple neuropsychiatric diseases.
113 sociation studies for major neurological and neuropsychiatric diseases.
114 Ion channel mutations can cause distinct neuropsychiatric diseases.
115 is axis in the treatment of inflammatory and neuropsychiatric diseases.
116 t and their relevance in the pathogenesis of neuropsychiatric diseases.
117 ANKS1B, a predicted risk gene for autism and neuropsychiatric diseases.
118 es may contribute to uncovering the basis of neuropsychiatric diseases.
119 n, for example, wakefulness, sleep, coma, or neuropsychiatric diseases.
120 inks between blood vessels and the origin of neuropsychiatric diseases.
121 rapeutic strategies in neurodegenerative and neuropsychiatric diseases.
122 slational relevance of preclinical models of neuropsychiatric diseases.
123 ssociated with certain neurodegenerative and neuropsychiatric diseases.
124 ealing mitochondrial defects associated with neuropsychiatric diseases.
125 alternations underlying human neurologic and neuropsychiatric diseases.
126 d framework for future analyses of miRNAs in neuropsychiatric diseases.
127 an emerging therapy for diverse, refractory neuropsychiatric diseases.
128 thogenesis of a wide range of neurologic and neuropsychiatric diseases.
129 erapeutic target for sleep disorders and for neuropsychiatric diseases accompanied by weakened sleep
130 men in behavior, mood, and susceptibility to neuropsychiatric disease across the adult lifespan.
131 ain insulin signaling can also contribute to neuropsychiatric diseases, affecting brain circuits invo
132 s consistent associations between a specific neuropsychiatric disease and a particular environmental
133 hypotheses derived from prior research into neuropsychiatric disease and cancer, gliomas may be expe
136 his study, we report eleven individuals with neuropsychiatric disease and copy-number variations span
137 n are associated with normal development and neuropsychiatric disease and differ across functionally
138 s how these data inform our understanding of neuropsychiatric disease and discuss the potential role
139 g underlying mechanisms and implications for neuropsychiatric disease and new treatment approaches.
140 ches to optimization of stimulation for each neuropsychiatric disease and we review the potential pos
142 and social deficits lie at the core of many neuropsychiatric diseases and are among the many behavio
144 oup, with variable overlap between different neuropsychiatric diseases and heterogeneously expressed
145 erentiation, and its dysregulation can cause neuropsychiatric diseases and increase cancer severity.
146 understanding of the heterogeneous nature of neuropsychiatric diseases and overcome existing bottlene
149 orrelate with impulsive behaviour in several neuropsychiatric diseases and there is post-mortem evide
150 ctory and other sensory maps, as well as for neuropsychiatric diseases and traits modulated by the BD
151 t opportunity of understanding complex human neuropsychiatric disease), and no work has characterized
152 e death, 14 elderly control patients with no neuropsychiatric disease, and 10 control patients with A
153 el candidate for intellectual disability and neuropsychiatric disease, and elucidate a mechanism of p
154 , urinary incontinence, gastrointestinal and neuropsychiatric diseases, and skeletal muscle disorders
155 nsity in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote co
158 Motor stereotypies occurring in early-onset neuropsychiatric diseases are associated with dysregulat
159 the pathogenesis and treatment of congenital neuropsychiatric diseases as well as idiopathic developm
161 mber of human clinical phenotypes, including neuropsychiatric diseases associated with dysregulation
162 ontal 5-HT1A receptors with implications for neuropsychiatric diseases associated with emotional dysf
163 neural substrates for the pathophysiology of neuropsychiatric disease-associated cognitive dysfunctio
164 erstanding of the regulome and the impact of neuropsychiatric disease-associated genetic risk variant
166 gion-specific mutations in Neurexin1alpha, a neuropsychiatric disease-associated synaptic molecule, i
167 echanistic insight to the processes by which neuropsychiatric diseases at a young age affect the risk
168 ovide strong evidence that familial risk for neuropsychiatric disease becomes more relevant to ASD et
170 e implicated in cognitive impairment in many neuropsychiatric diseases, but acetylcholine's specific
172 hat transcriptionally mimic autism and other neuropsychiatric diseases can be identified, and provide
173 substrates of choice, with implications for neuropsychiatric diseases characterized by dopaminergic
174 esults support the "dimensional" approach to neuropsychiatric disease classification and suggest pote
175 s was lower in febrile seizure patients with neuropsychiatric disease compared to febrile seizure pat
176 overy of new syndromes and genes involved in neuropsychiatric disease despite extensive genetic heter
177 treatment for various neurodegenerative and neuropsychiatric diseases despite the mechanism of actio
178 tion is characteristically impaired in major neuropsychiatric diseases, emphasizing its interest for
179 hizophrenia and the control patients without neuropsychiatric disease for the densities of any of the
182 we are likely transitioning into a phase of neuropsychiatric disease genetics in which the rate-limi
183 rare and de novo mutations, is transforming neuropsychiatric disease genetics through identifying on
189 Drug addiction and neurodegenerative and neuropsychiatric diseases have all been associated with
192 Alcoholism is one of the most prevalent neuropsychiatric diseases, having an enormous health and
193 erspective toward understanding and treating neuropsychiatric disease, highlighting the therapeutic p
194 TEP has been linked to neurodegenerative and neuropsychiatric diseases, highlighting this enzyme as a
195 eminal contributions to the understanding of neuropsychiatric disease; his works substantially added
196 come and Measures: The prevalence of defined neuropsychiatric disease in first-degree and second-degr
197 ) and the liver (P = 0.003), and 14 SNPs for neuropsychiatric disease in neuronal tissues (P = 0.007)
199 creased aggregation of neurodegenerative and neuropsychiatric disease in the context of the recently
202 ession; and find enrichment particularly for neuropsychiatric diseases in genomic regions with cell t
203 udies reported a decreased number of VENs in neuropsychiatric diseases in which the "embodied" dimens
205 aspartate receptors (NMDARs) to a variety of neuropsychiatric diseases including alcoholism, but deve
206 bsessive stereotypic behaviors, hallmarks of neuropsychiatric diseases including autism spectrum diso
207 in the SHANK3 human gene leads to different neuropsychiatric diseases including Autism Spectrum Diso
208 the cortex is a key pathological feature of neuropsychiatric diseases including depression, addictio
209 ilation are important features of a range of neuropsychiatric diseases including obsessive compulsive
211 contribute to the propensity for developing neuropsychiatric disease, including substance abuse diso
212 bilitating clinical feature of many forms of neuropsychiatric disease, including Tourette syndrome, o
213 ures related to either neuronal processes or neuropsychiatric diseases, including a human-specific mo
214 lopment of new therapeutics for treatment of neuropsychiatric diseases, including alcohol use disorde
216 gnition, and one that is impaired in several neuropsychiatric diseases, including attention deficit/h
217 Defects in this circuitry are linked to neuropsychiatric diseases, including bipolar disorder, s
218 and glia have been evaluated as mediators of neuropsychiatric diseases, including drug addiction.
219 STATEMENT Aggression is often comorbid with neuropsychiatric diseases, including drug addiction.
220 unctions are a common denominator in several neuropsychiatric diseases, including DS, but the contrib
222 (CSTC) circuit, which is implicated in many neuropsychiatric diseases, including obsessive-compulsiv
223 enesis or exploited in the treatment of many neuropsychiatric diseases, including Parkinson's disease
224 symmetry breaking is associated with several neuropsychiatric diseases, including schizophrenia and a
225 cortical interneurons has been implicated in neuropsychiatric diseases, including schizophrenia, auti
226 and it has been implicated in various other neuropsychiatric diseases, including schizophrenia, depr
227 er understand the mechanisms associated with neuropsychiatric diseases, including schizophrenia.
230 e novel therapeutic implications for several neuropsychiatric diseases involving dysregulation of the
231 the contribution of genetic risk factors to neuropsychiatric diseases is limited to abnormal neurode
232 cated in various developmental processes and neuropsychiatric diseases, its role in neurodevelopment
233 show that significant genetic liability for neuropsychiatric disease lies within prenatal eQTL and s
234 ht indicate that findings in mouse models of neuropsychiatric diseases may not be directly transferre
235 of a genomics-driven approach to uncovering neuropsychiatric disease mechanisms and facilitating the
240 cerebrospinal fluid from patients with three neuropsychiatric diseases of childhood for the presence
242 al data demonstrate that cardiometabolic and neuropsychiatric diseases originate in a suboptimal intr
243 molecular techniques to the understanding of neuropsychiatric disease, outlining the potential of zeb
244 able challenge to the study and treatment of neuropsychiatric diseases, owing to the complex interact
245 rogenesis, which is impaired in DS and other neuropsychiatric diseases, plays a key role in hippocamp
246 is population is exceptionally vulnerable to neuropsychiatric disease presentation during the hormona
247 al stimuli and is also implicated in diverse neuropsychiatric diseases, provides a less ambiguous mea
250 ding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to
251 magnesium transport dysfunction may increase neuropsychiatric disease risk and indicated that common
253 n reside in open chromatin, we reasoned that neuropsychiatric disease risk variants may affect chroma
255 nges are associated with increased offspring neuropsychiatric disease risk, and likely contribute to
258 including non-sectioned human tissue from a neuropsychiatric-disease setting, establishing a path fo
259 regulation is the most common feature across neuropsychiatric diseases, sex differences in how these
260 ases, including allergies and autoimmune and neuropsychiatric diseases, share common pathways of cell
261 number variants (CNVs) play a role in other neuropsychiatric diseases, so we assessed their associat
262 vioral and physiological process relevant to neuropsychiatric disease states including stress-related
266 es have identified rare CNVs associated with neuropsychiatric diseases such as autism, schizophrenia,
268 of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-tr
269 ities of PUFA status have been implicated in neuropsychiatric diseases such as major depression, bipo
270 essential to developing novel therapies for neuropsychiatric diseases such as OCD and ASDs with Hoxb
271 eaves neuropeptides and is a drug target for neuropsychiatric diseases such as post-traumatic stress
272 f behavioral control as observed in aging or neuropsychiatric diseases such as schizophrenia and addi
273 k "attractors" could be a defining aspect of neuropsychiatric diseases such as schizophrenia, represe
274 as Alzheimer's and Parkinson's disease, and neuropsychiatric diseases, such as autism and schizophre
275 investigate the underlying genetic origin of neuropsychiatric diseases, such as schizophrenia (SCZ).
278 en recently linked to neurodevelopmental and neuropsychiatric diseases, suggesting a role for RNA reg
279 se brain development is a critical epoch for neuropsychiatric disease susceptibility, we characterize
281 searchers in an approach to the diagnosis of neuropsychiatric disease that is inclusive and comprehen
282 There is an overlap between ALS, FTD, and neuropsychiatric disease that is pronounced in kindreds
283 of biomedical data provides a perspective on neuropsychiatric disease that may be otherwise elusive.
284 hese findings could provide new insight into neuropsychiatric diseases that involve improper generali
285 Apathy is a debilitating feature of many neuropsychiatric diseases, that is typically described a
286 ly with deep brain stimulation for different neuropsychiatric diseases, the axonal connectivity of th
287 abnormal kidney and muscle development, and neuropsychiatric disease, this Fat1 function may have im
288 morphological cerebral aberrations found in neuropsychiatric disease through exact neuropathological
289 traits ranging from Parkinson's disease and neuropsychiatric disease to cardiovascular and metabolic
290 ion medicine that better guide patients with neuropsychiatric diseases to optimal available treatment
291 ated conditions are among the most difficult neuropsychiatric diseases to treat pharmacologically, bu
292 acknowledged, including concomitant or past neuropsychiatric disease, use of corticosteroids, diseas
293 amily members of other neurodegenerative and neuropsychiatric disease was calculated using the relati
294 tal pathway and how its dysfunction leads to neuropsychiatric disease, we developed a method to conve
295 Given the possible involvement of Ih in neuropsychiatric diseases, we have also characterized Ih
296 ment and also in studies of neurological and neuropsychiatric diseases where disruptions of normal gl
297 y to developing schizophrenia, a devastating neuropsychiatric disease with high heritability but few
298 particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology,
300 their impact on vulnerability to drug abuse, neuropsychiatric diseases with differential expression a